5 completed, 1 terminated, 1 unknown, 1 withdrawn. 5 Phase 2, 2 Phase 1, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
| Early Phase 1 | 1 | Terminated 1 |
| Not applicable | 1 | Unknown 1 |
Follow Loss of Chromosome 17p: new trials by email Literature Review of Loss of Chromosome 17p trials Research Report on Loss of Chromosome 17p
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission | Early Phase 1 | Terminated | Rutgers, The State University of New Jersey | 2 | 2020-10-26 | 2023-06-26 |
| Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance Ibrutinib, Venetoclax - Chronic Lymphocytic Leukemia, Loss of Chromosome 17p | Phase 2 | Withdrawn | Kerry Rogers | 2020-03-11 | 2021-11-05 | |
| a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2, Melphalan Given IV - Multiple Myeloma, Plasma Cell Leukemia | Not applicable | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2018-01-05 | 2019-07-05 |
| Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Dexamethasone, Idasanutlin, Ixazomib Citrate - Loss of Chromosome 17p, Recurrent Plasma Cell Myeloma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 33 | 2015-12-30 | 2024-09-19 |
| Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation Ibrutinib, Laboratory Biomarker Analysis, Nivolumab - Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 37 | 2015-06-19 | 2024-03-20 |
| Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Atorvastatin Calcium, Cyclosporine, Fludarabine Phosphate - Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells | Phase 2 | Completed | Fred Hutchinson Cancer Center | 47 | 2012-09-25 | 2020-01-02 |
| Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma bortezomib, fludarabine phosphate, melphalan - Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p | Phase 1 | Completed | City of Hope Medical Center | 18 | 2011-03-01 | 2026-10-22 |
| Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation - B-Cell Prolymphocytic Leukemia, Hypodiploidy | Phase 2 | Completed | Fred Hutchinson Cancer Center | 16 | 2010-03-18 | 2019-06-11 |
Chromosome 17 deletion (8) · Multiple Myeloma (6) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Leukemia, Plasma Cell (3) · Lymphoma, Non-Hodgkin (3) · Hodgkin Disease (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Waldenstrom Macroglobulinemia (2) · Hematologic Neoplasms (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Prolymphocytic (1) · Leukemia, Prolymphocytic, B-Cell (1)
Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphoproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Leukemia (7) · Blood Protein Disorders (6) · Cardiovascular Diseases (6) · Hemorrhagic Disorders (6) · Hemostatic Disorders (6) · Neoplasms, Plasma Cell (6) · Paraproteinemias (6) · Vascular Diseases (6)
fludarabine phosphate (4) · Melphalan (3) · Peripheral Blood Stem Cell Transplantation (3) · Dexamethasone (2) · Mycophenolic Acid (2) · Tacrolimus (2) · Whole-Body Irradiation (2) · ibrutinib (2) · Atorvastatin (1) · Bortezomib (1) · Calcium Dobesilate (1) · Carmustine (1) · Cyclophosphamide (1) · Cyclosporine (1) · Cyclosporins (1)
Fred Hutchinson Cancer Center (2) · City of Hope Medical Center (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Kerry Rogers (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Rutgers, The State University of New Jersey (1)
United States (6) · China (1)
Firoozeh Sahebi, MD (1) · Kerry A Rogers, MD (1) · Lu G Qiu, Dr. (1) · Marco Mielcarek (1) · Mohamed Sorror (1) · Nitin Jain (1) · Roger Strair (1) · Shaji Kumar, M.D. (1)
P30CA015704 (2), P01CA018029 (1), P30CA072720 (1)